ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Publication Date: 1999-11-13
    Description: In sexual transmission of simian immunodeficiency virus, and early and later stages of human immunodeficiency virus-type 1 (HIV-1) infection, both viruses were found to replicate predominantly in CD4(+) T cells at the portal of entry and in lymphoid tissues. Infection was propagated not only in activated and proliferating T cells but also, surprisingly, in resting T cells. The infected proliferating cells correspond to the short-lived population that produces the bulk of HIV-1. Most of the HIV-1-infected resting T cells persisted after antiretroviral therapy. Latently and chronically infected cells that may be derived from this population pose challenges to eradicating infection and developing an effective vaccine.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Zhang, Z -- Schuler, T -- Zupancic, M -- Wietgrefe, S -- Staskus, K A -- Reimann, K A -- Reinhart, T A -- Rogan, M -- Cavert, W -- Miller, C J -- Veazey, R S -- Notermans, D -- Little, S -- Danner, S A -- Richman, D D -- Havlir, D -- Wong, J -- Jordan, H L -- Schacker, T W -- Racz, P -- Tenner-Racz, K -- Letvin, N L -- Wolinsky, S -- Haase, A T -- AI 28246/AI/NIAID NIH HHS/ -- AI 38565/AI/NIAID NIH HHS/ -- RR 00168/RR/NCRR NIH HHS/ -- New York, N.Y. -- Science. 1999 Nov 12;286(5443):1353-7.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Microbiology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/10558989" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; Anti-HIV Agents/therapeutic use ; CD4-Positive T-Lymphocytes/cytology/immunology/*virology ; Cell Cycle ; Cervix Uteri/virology ; Epithelial Cells/virology ; Female ; HIV Infections/drug therapy/*transmission/virology ; HIV-1/*physiology ; Lymph Nodes/virology ; *Lymphocyte Activation ; Macaca mulatta ; RNA, Viral/analysis ; Simian Acquired Immunodeficiency Syndrome/*transmission/virology ; Simian Immunodeficiency Virus/*physiology ; Time Factors ; Virus Replication
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 2
    Publication Date: 2000-10-20
    Description: With accumulating evidence indicating the importance of cytotoxic T lymphocytes (CTLs) in containing human immunodeficiency virus-1 (HIV-1) replication in infected individuals, strategies are being pursued to elicit virus-specific CTLs with prototype HIV-1 vaccines. Here, we report the protective efficacy of vaccine-elicited immune responses against a pathogenic SHIV-89.6P challenge in rhesus monkeys. Immune responses were elicited by DNA vaccines expressing SIVmac239 Gag and HIV-1 89.6P Env, augmented by the administration of the purified fusion protein IL-2/Ig, consisting of interleukin-2 (IL-2) and the Fc portion of immunoglobulin G (IgG), or a plasmid encoding IL-2/Ig. After SHIV-89.6P infection, sham-vaccinated monkeys developed weak CTL responses, rapid loss of CD4+ T cells, no virus-specific CD4+ T cell responses, high setpoint viral loads, significant clinical disease progression, and death in half of the animals by day 140 after challenge. In contrast, all monkeys that received the DNA vaccines augmented with IL-2/Ig were infected, but demonstrated potent secondary CTL responses, stable CD4+ T cell counts, preserved virus-specific CD4+ T cell responses, low to undetectable setpoint viral loads, and no evidence of clinical disease or mortality by day 140 after challenge.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Barouch, D H -- Santra, S -- Schmitz, J E -- Kuroda, M J -- Fu, T M -- Wagner, W -- Bilska, M -- Craiu, A -- Zheng, X X -- Krivulka, G R -- Beaudry, K -- Lifton, M A -- Nickerson, C E -- Trigona, W L -- Punt, K -- Freed, D C -- Guan, L -- Dubey, S -- Casimiro, D -- Simon, A -- Davies, M E -- Chastain, M -- Strom, T B -- Gelman, R S -- Montefiori, D C -- Lewis, M G -- Emini, E A -- Shiver, J W -- Letvin, N L -- AI-65301/AI/NIAID NIH HHS/ -- AI-85343/AI/NIAID NIH HHS/ -- CA-50139/CA/NCI NIH HHS/ -- P01 AI041521/AI/NIAID NIH HHS/ -- R01 CA050139/CA/NCI NIH HHS/ -- etc. -- New York, N.Y. -- Science. 2000 Oct 20;290(5491):486-92.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. dan_barouch@hotmail.com〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/11039923" target="_blank"〉PubMed〈/a〉
    Keywords: AIDS Vaccines/*therapeutic use ; Acquired Immunodeficiency Syndrome/*prevention & control ; Animals ; Antibodies, Viral/blood/immunology ; CD4 Lymphocyte Count ; CD4-Positive T-Lymphocytes/immunology ; Disease Progression ; HIV Antibodies/blood/immunology ; HIV Infections/immunology/*therapy/virology ; *HIV-1/genetics/immunology/physiology ; Humans ; Interleukin-2/genetics/immunology/*therapeutic use ; Lymphocyte Activation ; Macaca mulatta ; Neutralization Tests ; Recombinant Fusion Proteins/therapeutic use ; Simian Acquired Immunodeficiency Syndrome/immunology/prevention & ; control/therapy/virology ; Simian Immunodeficiency Virus/genetics/immunology/physiology ; T-Lymphocytes, Cytotoxic/immunology ; Vaccination ; Vaccines, DNA/*therapeutic use ; Viral Load ; Viremia ; Virus Replication
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 3
    Publication Date: 2002-03-23
    Description: To examine the role of T cell receptor (TCR) in gammadelta T cells in adaptive immunity, a macaque model was used to follow Vgamma2Vdelta2+ T cell responses to mycobacterial infections. These phosphoantigen-specific gammadelta T cells displayed major expansion during Mycobacterium bovis Bacille Calmette-Guerin (BCG) infection and a clear memory-type response after BCG reinfection. Primary and recall expansions of Vgamma2Vdelta2+ T cells were also seen during Mycobacterium tuberculosis infection of naive and BCG-vaccinated macaques, respectively. This capacity to rapidly expand coincided with a clearance of BCG bacteremia and immunity to fatal tuberculosis in BCG-vaccinated macaques. Thus, Vgamma2Vdelta2+ T cells may contribute to adaptive immunity to mycobacterial infections.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872146/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉   〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872146/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Shen, Yun -- Zhou, Dejiang -- Qiu, Liyou -- Lai, Xioamin -- Simon, Meredith -- Shen, Ling -- Kou, Zhongchen -- Wang, Qifan -- Jiang, Liming -- Estep, Jim -- Hunt, Robert -- Clagett, Michelle -- Sehgal, Prabhat K -- Li, Yunyaun -- Zeng, Xuejun -- Morita, Craig T -- Brenner, Michael B -- Letvin, Norman L -- Chen, Zheng W -- HL64560/HL/NHLBI NIH HHS/ -- R01 HL064560/HL/NHLBI NIH HHS/ -- R01 HL064560-04/HL/NHLBI NIH HHS/ -- R01 RR013601/RR/NCRR NIH HHS/ -- R01 RR013601-04/RR/NCRR NIH HHS/ -- RR13601/RR/NCRR NIH HHS/ -- New York, N.Y. -- Science. 2002 Mar 22;295(5563):2255-8.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Tuberculosis Research Unit, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/11910108" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; Immunity, Innate/immunology ; Immunologic Memory/immunology ; Lymphocyte Activation ; Lymphocyte Count ; Macaca/*immunology/*microbiology ; Mycobacterium bovis/*immunology ; Mycobacterium tuberculosis/*immunology ; Receptors, Antigen, T-Cell, gamma-delta/*immunology ; T-Lymphocytes/cytology/*immunology ; Tuberculosis/*immunology/microbiology
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 4
    Publication Date: 2013-12-20
    Description: A major challenge for the development of a highly effective AIDS vaccine is the identification of mechanisms of protective immunity. To address this question, we used a nonhuman primate challenge model with simian immunodeficiency virus (SIV). We show that antibodies to the SIV envelope are necessary and sufficient to prevent infection. Moreover, sequencing of viruses from breakthrough infections revealed selective pressure against neutralization-sensitive viruses; we identified a two-amino-acid signature that alters antigenicity and confers neutralization resistance. A similar signature confers resistance of human immunodeficiency virus (HIV)-1 to neutralization by monoclonal antibodies against variable regions 1 and 2 (V1V2), suggesting that SIV and HIV share a fundamental mechanism of immune escape from vaccine-elicited or naturally elicited antibodies. These analyses provide insight into the limited efficacy seen in HIV vaccine trials.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946913/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉   〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946913/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Roederer, Mario -- Keele, Brandon F -- Schmidt, Stephen D -- Mason, Rosemarie D -- Welles, Hugh C -- Fischer, Will -- Labranche, Celia -- Foulds, Kathryn E -- Louder, Mark K -- Yang, Zhi-Yong -- Todd, John-Paul M -- Buzby, Adam P -- Mach, Linh V -- Shen, Ling -- Seaton, Kelly E -- Ward, Brandy M -- Bailer, Robert T -- Gottardo, Raphael -- Gu, Wenjuan -- Ferrari, Guido -- Alam, S Munir -- Denny, Thomas N -- Montefiori, David C -- Tomaras, Georgia D -- Korber, Bette T -- Nason, Martha C -- Seder, Robert A -- Koup, Richard A -- Letvin, Norman L -- Rao, Srinivas S -- Nabel, Gary J -- Mascola, John R -- AI100645/AI/NIAID NIH HHS/ -- HHSN261200800001E/PHS HHS/ -- HHSN27201100016C/PHS HHS/ -- UM1 AI100645/AI/NIAID NIH HHS/ -- Z99 AI999999/Intramural NIH HHS/ -- ZIA AI005019-12/Intramural NIH HHS/ -- England -- Nature. 2014 Jan 23;505(7484):502-8. doi: 10.1038/nature12893. Epub 2013 Dec 18.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA. ; SAIC-Frederick, Frederick National Laboratory, NIH, Frederick, Maryland 21702, USA. ; 1] Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA [2] George Washington University, Washington DC 20052, USA. ; Los Alamos National Laboratories, Los Alamos, New Mexico 87545, USA. ; Department of Surgery, Duke University, Durham, North Carolina 27710, USA. ; 1] Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA [2] Sanofi-Pasteur, Cambridge, Massachusetts 02139, USA. ; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA. ; Human Vaccine Institute, Duke University, Durham, North Carolina 27710, USA. ; Fred Hutchison Cancer Research Center, Seattle, Washington 98109, USA. ; Biostatistics Research Branch, NIAID, NIH, Bethesda, Maryland 20892, USA. ; 1] Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA [2].〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/24352234" target="_blank"〉PubMed〈/a〉
    Keywords: AIDS Vaccines/*immunology ; Amino Acid Sequence ; Animals ; Antibodies, Neutralizing/immunology ; Disease Susceptibility/immunology ; Female ; Founder Effect ; HIV Antibodies/immunology ; HIV Infections/immunology/*prevention & control/*virology ; HIV-1/chemistry/*immunology ; Humans ; Immune Evasion/immunology ; Macaca mulatta ; Male ; Molecular Sequence Data ; Phylogeny ; Risk ; SAIDS Vaccines/*immunology ; Simian Acquired Immunodeficiency Syndrome/immunology/prevention & ; control/virology ; Simian Immunodeficiency Virus/chemistry/genetics/*immunology/physiology ; env Gene Products, Human Immunodeficiency Virus/immunology
    Print ISSN: 0028-0836
    Electronic ISSN: 1476-4687
    Topics: Biology , Chemistry and Pharmacology , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 5
    Publication Date: 2007-07-21
    Description: Understanding why some people establish and maintain effective control of HIV-1 and others do not is a priority in the effort to develop new treatments for HIV/AIDS. Using a whole-genome association strategy, we identified polymorphisms that explain nearly 15% of the variation among individuals in viral load during the asymptomatic set-point period of infection. One of these is found within an endogenous retroviral element and is associated with major histocompatibility allele human leukocyte antigen (HLA)-B*5701, whereas a second is located near the HLA-C gene. An additional analysis of the time to HIV disease progression implicated two genes, one of which encodes an RNA polymerase I subunit. These findings emphasize the importance of studying human genetic variation as a guide to combating infectious agents.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1991296/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉   〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1991296/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Fellay, Jacques -- Shianna, Kevin V -- Ge, Dongliang -- Colombo, Sara -- Ledergerber, Bruno -- Weale, Mike -- Zhang, Kunlin -- Gumbs, Curtis -- Castagna, Antonella -- Cossarizza, Andrea -- Cozzi-Lepri, Alessandro -- De Luca, Andrea -- Easterbrook, Philippa -- Francioli, Patrick -- Mallal, Simon -- Martinez-Picado, Javier -- Miro, Jose M -- Obel, Niels -- Smith, Jason P -- Wyniger, Josiane -- Descombes, Patrick -- Antonarakis, Stylianos E -- Letvin, Norman L -- McMichael, Andrew J -- Haynes, Barton F -- Telenti, Amalio -- Goldstein, David B -- G0200585/Medical Research Council/United Kingdom -- MC_U137884177/Medical Research Council/United Kingdom -- U19 AI067854/AI/NIAID NIH HHS/ -- U19 AI067854-03/AI/NIAID NIH HHS/ -- New York, N.Y. -- Science. 2007 Aug 17;317(5840):944-7. Epub 2007 Jul 19.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Center for Population Genomics and Pharmacogenetics, Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/17641165" target="_blank"〉PubMed〈/a〉
    Keywords: Cohort Studies ; DNA-Binding Proteins/genetics ; Disease Progression ; Female ; Genes, MHC Class I ; *Genome, Human ; HIV Infections/*genetics/immunology/therapy/*virology ; HIV-1/*physiology ; HLA-B Antigens/*genetics ; HLA-C Antigens/*genetics ; Haplotypes ; Humans ; Immediate-Early Proteins/genetics ; Major Histocompatibility Complex/*genetics ; Male ; Polymorphism, Single Nucleotide ; RNA, Untranslated ; Regression Analysis ; Viral Load
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 6
    Publication Date: 1985-10-04
    Description: The T-cell tropic retrovirus of macaque monkeys STLV-III has morphologic, growth, and antigenic properties indicating that it is related to HTLV-III/LAV, the etiologic agent of the acquired immune deficiency syndrome (AIDS) in humans. Four of six rhesus monkeys died within 160 days of STLV-III inoculation with a wasting syndrome, opportunistic infections, a primary retroviral encephalitis, and immunologic abnormalities including a decrease in T4+ peripheral blood lymphocytes. These data show that an immunodeficiency syndrome can be produced experimentally in a nonhuman primate by an agent from the HTLV-III/LAV group of retroviruses. The STLV-III-macaque system will thus provide a useful model for the study of antiviral agents and vaccine development for human AIDS.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Letvin, N L -- Daniel, M D -- Sehgal, P K -- Desrosiers, R C -- Hunt, R D -- Waldron, L M -- MacKey, J J -- Schmidt, D K -- Chalifoux, L V -- King, N W -- AI 20729/AI/NIAID NIH HHS/ -- CA 34979/CA/NCI NIH HHS/ -- CA 38205/CA/NCI NIH HHS/ -- etc. -- New York, N.Y. -- Science. 1985 Oct 4;230(4721):71-3.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/2412295" target="_blank"〉PubMed〈/a〉
    Keywords: Acquired Immunodeficiency Syndrome/*microbiology/pathology ; Animals ; Brain/pathology ; Deltaretrovirus ; *Disease Models, Animal ; Epitopes/analysis ; Humans ; Interleukin-2 ; Leukocyte Count ; Lymphocyte Activation ; Macaca mulatta ; Microscopy, Electron ; Pancreas/pathology ; *Retroviridae ; T-Lymphocytes/immunology
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...